Abstract: The present invention relates to oral compositions comprising cabozantinib salts and at least one pharmaceutically acceptable excipient and methods of using the oral compositions to increase the oral bioavailability of the cabozantinib and reduce the adverse events associate with the oral administration of cabozantinib. The invention also relates to methods for preparing cabozantinib lauryl sulfate salts.

Abstract: The present invention relates to oral compositions comprising cabozantinib salts and at least one pharmaceutically acceptable excipient and methods of using the oral compositions to increase the oral bioavailability of the cabozantinib and reduce the adverse events associate with the oral administration of cabozantinib. The invention also relates to methods for preparing cabozantinib lauryl sulfate salts.

Abstract: The present invention relates to oral compositions comprising cabozantinib salts and at least one pharmaceutically acceptable excipient and methods of using the oral compositions to increase the oral bioavailability of the cabozantinib and reduce the adverse events associate with the oral administration of cabozantinib. The invention also relates to methods for preparing cabozantinib lauryl sulfate salts.

Abstract: The present invention relates methods for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy a therapeutic amount of cabozantinib lauryl sulfate salt, preferably in a capsule form. The method allows the administration of the therapeutic amount of cabozantinib lauryl sulfate salt in a fed state or a fasted state and the administration does not exhibit a food effect.

Abstract: The present invention relates methods for treating thyroid cancer, renal cell carcinoma or hepatocellar carcinoma comprising orally administering to a patient in need of such therapy a therapeutic amount of cabozantinib lauryl sulfate salt, preferably in a capsule form. The method allows the administration of the therapeutic amount of cabozantinib lauryl sulfate salt in a fed state or a fasted state and the administration does not exhibit a food effect.

Abstract: A biomedical measuring device, such as a test strip, has a simple structure, by which analyte can be measured easily using a small amount of specimen. In embodiments, the test strip generally includes a plastic first film layer having structure defining an aperture for retaining the reacting components, a porous membrane coupled to an inner-facing surface of the first film layer and configured to reduce background signal, an absorbent pad coupled to the porous membrane and first film layer to sandwich the porous membrane therebetween, the absorbent pad being configured for rapid absorption, and a plastic second film layer coupled to the absorbent pad, the second film layer being configured to provide a barrier to prevent liquid from leaking out of the test strip during use. The test strip can be easily used with an optical sensing device coupled to or containing an analyzer device (or reader device) for quickly detecting and measuring the analyte concentration.

Abstract: Bis-intercalating peptide compounds having Formula I, which are capable of binding DNA and exerting a cytotoxic effect on cells, such as microbial, viral or tumour cells, and conjugates comprising the compounds linked to a targeting moiety, such as an antibody. The compounds and conjugates may be used in the treatment of cancer or a microbial or viral infection, or as diagnostic agents or labelling agents.

Abstract: The present invention relates methods for treating chronic myeloid leukemia and/or lymphoblastic leukemia by orally administering to a patient in need of such a therapeutic amount of dasatinib lauryl sulfate salt, preferably in a tablet, capsule or suspension form. The method allows the administration of the therapeutic amount of dasatinib lauryl sulfate salt a fed state or a fasted state and the administration does not exhibit a food effect.

Abstract: Disclosed are compositions, methods, and kits relating to amplifying and detecting RNA using Co-Primers and conditionally active reverse transcription primers. The conditionally active reverse transcriptase primers work in concert with dual Co-Primer assays to improve sensitivity toward RNA targets without detracting from the improved amplification specificity of the associated Co-Primers.

Abstract: Systems, methods, and apparatus are provided for external control testing of an assay system.

Abstract: Provided herein are benzenesulfonamide derivatives having Formula (III), pharmaceutical compositions comprising said compounds, and method for using said compounds for disrupting proteins/polypeptides, protein/polypeptide function, and for the treatment of diseases through the disruption of proteins or polypeptides involved in the etiology of the disease. Said compounds comprise fluorinated benzene sulfonamide structures.

Abstract: A system for the generation of mechanical or electrical energy from heat energy, where increasing a height or pressure in a liquid chamber of the system containing a liquid increases an efficiency of the system up to a hundred percent or increases such efficiency until a critical temperature or pressure of the vapor (gas) is reached at the bottom of liquid chamber or in the boiler of the system depending upon the increment in height, pressure and the type of liquid used in the system. An increase in height of the system for such increased efficiency can be adjusted to a smaller height by maintaining a series of liquid and gas chambers where the vapor flows through the series of chambers or by adding pressure valves. The heat energy from high to low temperature sources can be convened to mechanical and electrical energy.

Abstract: A robot with the perception capability of livestock and poultry information and a mapping approach based on autonomous navigation are disclosed. The robot includes a four-wheeled vehicle (3), an autonomous navigation system, a motion module and an information acquisition module. The autonomous navigation system includes a LiDAR (10), a RGB-D camera (9), an inertial measurement unit (5), an odometer and a main control module (12). The information acquisition module includes two thermal imagers (6), an environmental detection sensor module (8) and a wireless transmission module (11). The robot is controlled in indoor working environment, and simultaneously information about surrounding environment during movement is obtained with the autonomous navigation system; positioning locations are obtained through data processing and a global map is constructed, which can improve positioning accuracy, reduce dependence on breeders, realize automatic environment detection.

Abstract: Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ?3.9 when administered at the same toxin dose.

Abstract: The present invention relates to capsules comprising dasatinib lauryl sulfate salt.

Abstract: Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ?3.9 when administered at the same toxin dose.

Abstract: A computing device: obtains an electronic image of a receipt, the receipt containing numerical information with no predefined format; automatically captures the numerical information in the obtained electronic image; organizes the captured numerical information; enables editing of the captured numerical information; enables viewing of the captured numerical information in a desired format; and enables combining the captured numerical information in the obtained electronic image with other numerical information previously captured from electronic images of other receipts into a report having predetermined categories. The report summarizes expense information contained in the captured numerical information in the obtained electronic image with the other numerical information previously captured from the electronic images of the other receipts.

Abstract: The present invention relates to polymorphic forms of dasatinib lauryl sulfate salt.

Abstract: The present invention relates to kinase inhibitor C8-C16 aliphatic sulfate salts, compositions containing kinase inhibitor C8-C16 aliphatic sulfate salts and uses thereof.

Abstract: The present invention relates to polymorphic forms of nilotinib lauryl sulfate salt.